The Economist-20241130期「China」Obesity: The weight is over
02 全文梳理
【para1】引入话题👉马斯克“带货”减肥药Wegovy
【para2】进军中国👉11月17日，Wegovy获批进入中国市场
【para3-4】分析现状
-para3 中国肥胖率升高
-para4 医疗体系负担加重，官方积极应对
【para5】购买门槛👉在华限量销售以保证全球供应，价格偏高且未纳入医保
【para6】竞争激烈👉各方加速入局，供需趋于平衡
03 原文阅读 536words
Obesity: The weight is over
Wegovy comes to China
Obesity: The weight is over
Wegovy comes to China
[5] Not everyone will have access to them at first. Novo Nordisk has said it will limit initial sales of Wegovy in China so as not to affect the supply to other markets. A month's supply of the drug will cost 1,400 yuan ($190), according to local media. That is a fraction of the $1,350 it costs in America, but still a substantial expense for many Chinese. They would also have to pay it out of pocket, as Wegovy is not available on the public health-insurance system.
[6] Nevertheless, Nomura, a bank, estimates that by 2033 the Chinese weight-loss-drug market might be worth over $11bn a year. Wegovy will be only one part of the picture. Eli Lilly, an American pharmaceutical company, is expected to market its own GLP-1 drug in China soon (it already has regulatory approval). And in 2026 Novo Nordisk's patent for semaglutide will expire in China, allowing local firms to sell cheap generic versions of Wegovy. At least 11 such drugs are going through clinical trials, according to a count in June by Reuters, a news agency. Supply may begin to catch up with demand. ■
每天一篇经济学人团队
来自北大、复旦、南大、人大、
北外、上外、外交学院等
重点高校专业的学长学姐（CATTI一笔二笔）
多年教学经验的留学老师
十余年外刊翻译经验的英语大牛
专注打磨阅读训练营1700天+
输出高质量内容、高水平译文
